Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.5 Billion KRW | -107.9% |
| 2022 | 31.74 Billion KRW | 22.29% |
| 2021 | 25.95 Billion KRW | 20.47% |
| 2020 | 21.54 Billion KRW | 9.95% |
| 2019 | 19.59 Billion KRW | 500.46% |
| 2018 | -4.89 Billion KRW | -178.11% |
| 2017 | 6.26 Billion KRW | 6.08% |
| 2016 | 5.9 Billion KRW | 63.25% |
| 2015 | 3.61 Billion KRW | 133.0% |
| 2014 | -10.96 Billion KRW | -376.6% |
| 2013 | 3.96 Billion KRW | 91.15% |
| 2012 | 2.07 Billion KRW | 49.56% |
| 2011 | 1.38 Billion KRW | -29.84% |
| 2010 | 1.97 Billion KRW | 85.39% |
| 2009 | 1.06 Billion KRW | 106.63% |
| 2008 | -16.07 Billion KRW | -1702.77% |
| 2007 | 1 Billion KRW | -67.75% |
| 2006 | 3.11 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.08 Billion KRW | -46.35% |
| 2024 Q1 | 2.02 Billion KRW | 127.42% |
| 2023 Q4 | -7.37 Billion KRW | -252.71% |
| 2023 Q1 | 2.91 Billion KRW | -13.84% |
| 2023 Q3 | 4.83 Billion KRW | 265.86% |
| 2023 Q2 | -2.91 Billion KRW | -199.96% |
| 2023 FY | -2.5 Billion KRW | -107.9% |
| 2022 Q1 | 9.71 Billion KRW | 208.87% |
| 2022 FY | 31.74 Billion KRW | 22.29% |
| 2022 Q4 | 3.38 Billion KRW | -70.56% |
| 2022 Q3 | 11.48 Billion KRW | 60.5% |
| 2022 Q2 | 7.15 Billion KRW | -26.28% |
| 2021 Q2 | 3.1 Billion KRW | 677.12% |
| 2021 Q1 | 399.6 Million KRW | 25.1% |
| 2021 FY | 25.95 Billion KRW | 20.47% |
| 2021 Q4 | 3.14 Billion KRW | -59.36% |
| 2021 Q3 | 7.73 Billion KRW | 149.08% |
| 2020 Q2 | 2.42 Billion KRW | -25.08% |
| 2020 Q4 | 319.43 Million KRW | -93.48% |
| 2020 Q3 | 4.9 Billion KRW | 102.32% |
| 2020 Q1 | 3.23 Billion KRW | 183367.07% |
| 2020 FY | 21.54 Billion KRW | 9.95% |
| 2019 Q1 | 4.72 Billion KRW | 150.91% |
| 2019 FY | 19.59 Billion KRW | 500.46% |
| 2019 Q4 | -1.76 Million KRW | -100.05% |
| 2019 Q3 | 3.83 Billion KRW | 167.85% |
| 2019 Q2 | 1.43 Billion KRW | -69.74% |
| 2018 Q1 | 4.65 Billion KRW | 55.68% |
| 2018 FY | -4.89 Billion KRW | -178.11% |
| 2018 Q2 | 1.74 Billion KRW | -62.46% |
| 2018 Q3 | -2.01 Billion KRW | -215.1% |
| 2018 Q4 | -9.28 Billion KRW | -361.65% |
| 2017 Q3 | -643.96 Million KRW | -128.3% |
| 2017 FY | 6.26 Billion KRW | 6.08% |
| 2017 Q1 | 1.64 Billion KRW | 93.67% |
| 2017 Q2 | 2.27 Billion KRW | 38.45% |
| 2017 Q4 | 2.98 Billion KRW | 564.23% |
| 2016 Q3 | 1.11 Billion KRW | -26.18% |
| 2016 Q4 | 848.65 Million KRW | -24.16% |
| 2016 Q1 | 2.42 Billion KRW | 0.0% |
| 2016 Q2 | 1.51 Billion KRW | -37.41% |
| 2016 FY | 5.9 Billion KRW | 63.25% |
| 2015 Q3 | -2.2 Billion KRW | -191.58% |
| 2015 Q1 | 791.33 Million KRW | 124.27% |
| 2015 FY | 3.61 Billion KRW | 133.0% |
| 2015 Q2 | 2.41 Billion KRW | 204.81% |
| 2014 Q2 | -4.1 Billion KRW | -260.41% |
| 2014 Q1 | 2.56 Billion KRW | 318.09% |
| 2014 FY | -10.96 Billion KRW | -376.6% |
| 2014 Q4 | -3.26 Billion KRW | 25.66% |
| 2014 Q3 | -4.38 Billion KRW | -6.76% |
| 2013 FY | 3.96 Billion KRW | 91.15% |
| 2013 Q1 | 1.21 Billion KRW | 897.32% |
| 2013 Q2 | 385.79 Million KRW | -68.3% |
| 2013 Q3 | 404.08 Million KRW | 4.74% |
| 2013 Q4 | 612.49 Million KRW | 51.58% |
| 2012 Q1 | 659.76 Million KRW | 450.25% |
| 2012 Q2 | 209.52 Million KRW | -68.24% |
| 2012 Q3 | 524.51 Million KRW | 150.34% |
| 2012 FY | 2.07 Billion KRW | 49.56% |
| 2012 Q4 | 122.04 Million KRW | -76.73% |
| 2011 Q2 | 162.02 Million KRW | -81.67% |
| 2011 Q1 | 884.09 Million KRW | 128.11% |
| 2011 FY | 1.38 Billion KRW | -29.84% |
| 2011 Q4 | 119.9 Million KRW | -73.03% |
| 2011 Q3 | 444.57 Million KRW | 174.39% |
| 2010 Q3 | 82.89 Million KRW | -86.66% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 1.97 Billion KRW | 85.39% |
| 2010 Q2 | 621.25 Million KRW | 0.0% |
| 2010 Q4 | 387.56 Million KRW | 367.54% |
| 2009 Q1 | -7.84 Billion KRW | -645.21% |
| 2009 FY | 1.06 Billion KRW | 106.63% |
| 2009 Q4 | 54.28 Million KRW | -37.04% |
| 2009 Q3 | 86.2 Million KRW | 2.4% |
| 2009 Q2 | 84.18 Million KRW | 101.07% |
| 2008 Q4 | 1.43 Billion KRW | 137.03% |
| 2008 FY | -16.07 Billion KRW | -1702.77% |
| 2008 Q3 | -3.88 Billion KRW | 32.9% |
| 2008 Q2 | -5.78 Billion KRW | -958.23% |
| 2008 Q1 | -547.09 Million KRW | -253.19% |
| 2007 Q2 | 518.87 Million KRW | 0.0% |
| 2007 Q4 | 357.13 Million KRW | -47.04% |
| 2007 FY | 1 Billion KRW | -67.75% |
| 2007 Q3 | 674.33 Million KRW | 29.96% |
| 2006 FY | 3.11 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 65.096% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 104.322% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 95.794% |
| HANDOK Inc. | -28.79 Billion KRW | 91.296% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 70.216% |
| Yuhan Corporation | 93.5 Billion KRW | 102.68% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 122.535% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 89.898% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 101.714% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 171.436% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -20.855% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 44.608% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 111.223% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 65.096% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 88.031% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 169.946% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 97.881% |
| JW Holdings Corporation | 19.02 Billion KRW | 113.173% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 96.824% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 101.179% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 106.773% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 95.628% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 140.943% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 250.668% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 150.081% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 65.096% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 106.78% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 102.248% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 106.773% |
| Yuhan Corporation | 93.5 Billion KRW | 102.68% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 84.576% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 35.327% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 140.96% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 106.773% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 113.257% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 105.193% |
| CKD Bio Corp. | -24.19 Billion KRW | 89.64% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 110.48% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 109.135% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 108.418% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 95.628% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 105.332% |
| Boryung Corporation | 40.2 Billion KRW | 106.234% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 92.0% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -0.0% |
| JW Lifescience Corporation | 28.14 Billion KRW | 108.906% |